Literature DB >> 12522229

New perspectives for prion therapeutics meeting. Prion disease treatment's early promise unravels.

Peter Follette.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12522229     DOI: 10.1126/science.299.5604.191

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  5 in total

Review 1.  Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances.

Authors:  Maria Caramelli; Giuseppe Ru; Pierluigi Acutis; Gianluigi Forloni
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  Enhanced stability of human prion proteins with two disulfide bridges.

Authors:  Tuomas P J Knowles; Ralph Zahn
Journal:  Biophys J       Date:  2006-06-02       Impact factor: 4.033

3.  A possible pharmacological explanation for quinacrine failure to treat prion diseases: pharmacokinetic investigations in a ovine model of scrapie.

Authors:  Véronique Gayrard; Nicole Picard-Hagen; Catherine Viguié; Valerie Laroute; Olivier Andréoletti; Pierre-Louis Toutain
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

4.  Uptake and efflux of quinacrine, a candidate for the treatment of prion diseases, at the blood-brain barrier.

Authors:  Shinya Dohgu; Atsushi Yamauchi; Fuyuko Takata; Yasufumi Sawada; Shun Higuchi; Mikihiko Naito; Takashi Tsuruo; Susumu Shirabe; Masami Niwa; Shigeru Katamine; Yasufumi Kataoka
Journal:  Cell Mol Neurobiol       Date:  2004-04       Impact factor: 5.046

5.  Styryl-based and tricyclic compounds as potential anti-prion agents.

Authors:  Erika Chung; Frances Prelli; Stephen Dealler; Woo Sirl Lee; Young-Tae Chang; Thomas Wisniewski
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.